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rognostic Role of B-Type Natriuretic Peptide
evels in Patients With Type 2 Diabetes Mellitus
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OBJECTIVES We hypothesized that B-type natriuretic peptide (BNP) levels can predict cardiac mortality
in diabetic patients.
BACKGROUND Detection of cardiovascular disease in diabetics can be difficult until overt events occur.
METHODS A total of 482 diabetics (majority male with type 2 diabetes) at the Veterans Affairs Medical
Center San Diego were divided into two groups: 1) referred patients for echocardiogram on
the basis of clinical suspicion of cardiac dysfunction (referred [R], n  180); 2) patients
randomly selected from the diabetic clinic without any suspicion of cardiac dysfunction (not
referred [N-R], n  302). We examined cardiac events and all-cause mortality in relation to
initial BNP levels during the follow-up.
RESULTS A total of 71 (14.7%) patients died during this period: 52 of 180 (29%) in the R group (30
of 52 [58%] cardiac, 10 of 52 [19%] non-cardiac, 2 of 52 [4%] renal, 10 of 52 [19%] unknown
cause) and 19 of 302 (6%) in N-R group (6 of 19 [32%] cardiac). The median BNP level in
the R and N-R groups who died of cardiac, non-cardiac, and unknown cause was 537 and 87,
80 and 53, and 343 and 38 pg/ml, respectively. The receiver-operating characteristic (ROC)
values for mortality in two groups in relation to BNP revealed the area under the curve to be
0.720 and 0.691, respectively (p  0.01 in both). Among commonly used prognostic indicators
in diabetics, only the ROC for triglycerides was significant. The most accurate cut-point in both
the N-R group (87%) and R group (61%) was 120 pg/ml of BNP. Cox regression analysis showed
BNP to be the most significant predictor of all-cause mortality in the R group. There was a
marked decrease in survival in the patient group with BNP 120 pg/ml.
CONCLUSIONS B-type natriuretic peptide appears to be a reliable predictor of future cardiac and all-cause
mortality in diabetic patients. (J Am Coll Cardiol 2004;44:1047–52) © 2004 by the
American College of Cardiology Foundationl
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there were 12.1 million people in the U.S. in 2002 who
ere diagnosed with diabetes, and by 2020 that number will
row to 17.4 million (1). Diabetes is a major risk factor for
ncreased cardiovascular events, and diabetic individuals
ave a 200% to 400% greater risk for vascular disease than
on-diabetics. Recent advances in the treatment of coronary
isease have improved survival for diabetics and non-
iabetics, but diabetics still have double the case fatality rate
ompared with non-diabetics (2). Diabetic individuals also
ave an increased frequency of silent ischemia, systolic and
iastolic left ventricular (LV) dysfunction, and cardiac
utonomic neuropathy (3). The high frequency of modifi-
ble risk factors provides great opportunities for prevention,
he cornerstones of therapy being glycemic control, aggres-
ive risk factor modification, and ongoing patient surveil-
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edicine Veteran’s Affairs Medical Center and University of California, San Diego,
an Diego, California. Dr. Maisel is a consultant for Biosite Inc., and Dr. Kazanegra
nd Paul Clopton have received salary support from Biosite. Dr. Marc A. Silver acted
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Manuscript received April 2, 2004; revised manuscript received May 6, 2004,
Jccepted May 6, 2004.ance and monitoring to facilitate early disease detection and
rompt intervention.
B-type natriuretic peptide (BNP) is a cardiac neurohor-
one predominantly released from the ventricles in re-
ponse to LV volume expansion and pressure overload.
-natriuretic peptide levels are known to be elevated in
atients with LV dysfunction and correlate with New York
eart Association functional class, prognosis, and systolic
nd diastolic LV dysfunction findings on echocardiography
4–8). The availability of rapid BNP measurements can
elp reliably detect the presence or absence of LV dysfunc-
ion in patients with diabetes (4,9–11). Because BNP has
lso been shown to be an effective tool in screening in
iabetes, we designed this prospective study in diabetic
atients to see whether BNP can also help predict morbidity
nd mortality.
ETHODS
tudy population. The University of California San Diego
nstitutional Review Board approved this study. The par-
icipants included 482 diabetic patients recruited between
une 1999 and February of 2001 from San Diego Veterans
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Prognostic Value of BNP in Diabetics September 1, 2004:1047–52ffairs Medical Center. These patients were divided into
wo groups:
. Referred (R): those subjects referred by physician or
nurse practitioner for echocardiography on the basis of
clinical suspicion of cardiac dysfunction, most com-
monly shortness of breath, n  180.
. Not referred (N-R): those subjects randomly selected
and recruited from the diabetic clinic. In this group of
patients, there was no suspicion of cardiac dysfunction,
no referrals to cardiologists, and no previous records of
echocardiography with abnormalities of LV function
(systolic or diastolic), n  302.
Patients were followed for mean time period of 827 
84 days and 864  207 days (mean  SD), respectively, at
an Diego Veterans Affairs Medical Center. Most were
ales with type 2 diabetes (95% in R and 84% in N-R
roups, respectively). Death certificates were used to deter-
ine the cause of mortality in patients who did not die in
he hospital. Patients designated to “unknown cause of
eath” group, died outside San Diego county, and death
ertificates were not available. For simplicity, heart failure
HF) with preserved systolic function is referred to as
diastolic dysfunction.”
easurement of BNP levels. During initial evaluations, a
mall sample (5 cc) was collected into tubes containing
otassium EDTA (1 mg/ml blood). B-natriuretic peptide
as measured using the Triage B-Type Natriuretic Peptide
est (Biosite Incorporated, San Diego, California). The
riage BNP test is a fluorescence immunoassay for the
uantitative determination of BNP in whole blood and
lasma specimens and has been recently characterized with
egard to precision, analytical sensitivity, and stability (12–
4) B-natriuretic peptide values were determined on site
tilizing the point-of-care method with either whole blood
r plasma samples.
tatistical analysis. Descriptive statistics were computed
or each group. Median BNP levels are reported for sub-
roups of patients and compared with Mann-Whitney U
ests. Box and whisker plots were used to show BNP
istributions of subgroups based on outcomes. Receiver-
perating characteristic (ROC) curves were calculated for
rediction of all-cause death by plasma BNP concentration.
n addition, summary statistics for ROC curves were calcu-
ated for prediction of all-cause mortality by other markers
ncluding triglycerides, high-density lipoprotein, low-
ensity lipoprotein, and HbA1c. Sensitivity, specificity,
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
EF  ejection fraction
HF  heart failure
LV  left ventricular
ROC  receiver-operating characteristicositive predictive value, negative predictive value, and nccuracy were computed for BNP using a selection of
ossible cut-points. Accuracy is defined as true-positive plus
rue-negative cases divided by the total sample size. The
aplan-Meier survival analysis was used to estimate survival
or patients with BNP levels above and below 120 pg/ml,
nd the significance of differences was calculated by the
og-rank test. Cox regression was used to test for the
ombined predictive power of BNP and other variables.
ESULTS
able 1 shows the characteristics of all 482 patients subdi-
ided by whether or not they were initially referred for
ardiac work-up. Both groups had a high preponderance of
ales, as they were recruited from the Veterans Affairs
edical Center in San Diego. Referred patients were
ounger with a higher frequency of type 2 diabetes. As
xpected, the referred group had a higher incidence of
revious cardiac disease (51% vs. 12%) and, except for
ngiotensin-converting enzyme inhibitors, angiotensin re-
eptor blockers, and statins, were taking more cardiac
edications. Table 2 shows the mortality in the study
opulation. There were 52 (29%) deaths during the
ollow-up period in the referred group and 19 (6%) in the
ot-referred group. In the referred group, 30 (58%) deaths
ere due to cardiac causes, 10 (19%) were due to non-
ardiac causes, 2 (4%) were renal, and in 10 patients death
ertificates could not be located (death occurred outside of
able 1. Patient Characteristics
Referred
Not
Referred p Value
otal 180 302
ales 170 (94%) 291 (96%) 0.320
ean age (yrs) 52  20 61  12 0.001
ean follow-up time (days) 827  384 864 207 0.174
ype 2 (others were type 1) 171 (95%) 255 (84%) 0.001
istory of cardiac disease 91 (51%) 37 (12%) 0.001
edication history
ACE-I/ARB 114 (67%) 215 (74%) 0.366
Statins 96 (57%) 183 (63%) 0.479
Fibrates 13 (77%) 38 (13%) 0.105
Furosemide 86 (51%) 64 (22%) 0.001
Insulin 68 (40%) 153 (53%) 0.033
Oral hypoglycemics 157 (92%) 288 (99%) 0.001
Beta-blockers 29 (32.5%)* 42 (13.9%) 0.001
Aspirin 98 (54.4%) 183 (60.5%) 0.214
n  89.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor
locker.
able 2. Mortality in the Study Population
Cause of Death* Referred Not-Referred
ardiac 30 6
on-cardiac 10 8
enal 2 0
nknown† 10 5
otal 52 (29%) 19 (6%)
According to the cause of death listed in death certificates; †Death certificates could
ot be located in patients who died outside San Diego County.
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September 1, 2004:1047–52 Prognostic Value of BNP in Diabeticsan Diego County). Similarly 6 (32%) died of cardiac causes
n the not-referred group, 8 (42%) from non-cardiac causes,
nd 5 (26%) were unknown.
Figure 1 shows box-whisker representations of BNP
evels for survivors and non-survivors in the referred and
ot-referred groups. The initial median BNP level in
atients who were alive at the end of follow-up period was
igher in the referred than the not-referred group (76 vs. 14
g/ml, respectively; p 0.001). Similarly, the initial median
NP level in patients who had died by the end of follow-up
eriod was higher in the referred than the not-referred
roup patients (312 vs. 40 pg/ml, respectively, p  0.0001
or all deaths and 537 vs. 87 pg/ml, respectively, p  0.009
or cardiac deaths). Patients who died during the follow-up
eriod had higher initial BNP levels than those that
urvived in both the referred (312 vs. 76 pg/ml; p  0.001)
nd the not-referred groups (40 vs. 14 pg/ml; p  0.005).
Figure 2 shows the ROC curve for initial BNP levels
redicting all-cause death during the follow-up period. In
oth the referred and not-referred populations, the area
nder the curve was significant at 0.720 and 0.691, respec-
ively (p  0.01 in both cases).
Table 3 shows different statistical values and 95% confi-
ence intervals predicting mortality in diabetic patients
sing four different cut-points of initial BNP levels 60,
80, 100, 120 pg/ml in both the referred and not-
eferred subgroups. The sensitivity and positive predictive
alue were higher in the referred versus not-referred groups
cross the range of BNP cut-points. A BNP level of 120
g/ml gave a 69% sensitivity and a 40% positive predictive
alue.
The specificity and negative predictive value was higher
n the not-referred versus referred group across the range of
igure 1. Shows the median B-natriuretic peptide (BNP) values (pg/ml)
or different mortality causes. In this graph, there were two patients who
ied of renal causes. Their BNP levels were 1,300 and 805. *p  0.005
hen comparing using BNP between the people who died due to all causes
nd who survived in the non-referred group; †p  0.001 when comparing
sing BNP between the people who died due to all causes and who survived
n the referred group. Boxes show 25th and 75th percentile with medians
iven; whiskers show 10th and 90th percentiles.NP cut-points. The most accurate cut-point in the not- feferred group was also a BNP level of 120 pg/ml (87%).
his gave a 91% specificity and a 95% negative predictive
alue. Table 3 also shows the positive and negative likeli-
ood ratio of predicting all-cause mortality in non-referred
roup at the BNP levels of 20, 40, 60, 80, 100, and 120
g/ml; the likelihood ratio in this group at BNP level of 120
g/ml was 5.66.
Table 4 shows the values for the area under the ROC
urve for different markers (cholesterol subtypes, triglycer-
des, and HbA1c), as compared with BNP, in predicting: 1)
ll-cause mortality; and 2) cardiac mortality in diabetics. In
he referred group, BNP was the most accurate at predicting
ll-cause mortality as well as cardiac death, with only
riglyceride level showing a significant predictive value. In
he not-referred population, BNP also had the highest area
nder the ROC curve (p  0.005 for all-cause mortality).
Cox regression analysis provided a multivariable approach
o predict all-cause mortality from BNP (120 pg/ml vs.
120 pg/ml), age, gender, and type of diabetes mellitus. In
he referred patients, BNP was the only significant predictor
f the all-cause mortality (p  0.003). In the not-referred
roup, only age (p  0.012) and BNP (p  0.042) were
ignificant predictors of all-cause mortality.
Echocardiographic data was only available on a subset of
he subjects in the not-referred group (91 of 302 cases). A
ox regression in this subset of patients including LV
unction, ejection fraction (EF), and BNP yielded no
ignificant predictors of survival. By contrast, in the data for
he referred group, BNP was significant (p  0.02), and no
ther predictors were significant. Some subjects were lost
igure 2. Area under receiver-operating characteristic curve (AUC) values
or B-natriuretic peptide in predicting death (all-cause including cardiac
eath) in study groups with and without referral.rom this second analysis due to missing quantitative values
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Prognostic Value of BNP in Diabetics September 1, 2004:1047–52or EF. If EF is removed from the model, BNP is still
ignificant (p 0.004), and no other predictors are significant.
Figure 3 shows the Kaplan-Meier survival curves of
atient subgroups with BNP values 120 pg/ml and 120
g/ml in both the referred and not-referred groups of
atients. All-cause mortality is shown. In both the sub-
roups, survival was significantly reduced over time as a
unction of BNP level, especially in patients referred for
ardiac work-up.
ISCUSSION
he Framingham study firmly established the epidemio-
ogic link between diabetes and LV dysfunction (15). In the
resence of coronary disease, diabetes is an independent
actor for deterioration of cardiac function (16). While early
etection of LV dysfunction enables administration of
reatment that can improve survival and increase well-being
17–19), ventricular dysfunction may be difficult to diagnose
ecause patients may be asymptomatic or have non-specific
ymptoms, and abnormal findings on physical examination
re often absent (20,21). A test that not only elucidates the
able 3. Effect of Using Different Cutoff Values for BNP on Sen
alue, and Accuracy in Predicting Death (All-Cause Including th
BNP Cutoff
(pg/ml) Sensitivity Specificity
Positive Pred
Value
eferred
60 83 (70–91) 43 (34–52) 37 (29–46
80 79 (41–59) 50 (41–59) 39 (30–49
100 71 (57–83) 55 (46–63) 39 (29–49
120 69 (55–81) 58 (49–66) 40 (30–51
ot-Referred
20 68 (42–89) 60 (54–66) 10 (6–17)
40 53 (28–77) 75 (69–80) 12 (7–22)
60 47 (23–72) 82 (77–86) 15 (8–27)
80 42 (19–68) 84 (80–88) 15 (7–28)
100 37 (15–63) 88 (84–91) 17 (7–32)
120 32 (11–58) 91 (87–94) 19 (8–38)
NP  B natriuretic peptide.
able 4. Comparison of Receiver-Operating Characteristic Curve
redicting All Causes of Mortality and Cardiac Mortality
Marker
Referred
AUC CI p
ll Causes of Mortality (Including Cardiac and Unknown Cause of D
TGL 0.638 0.539–0.737
HDL 0.553 0.445–0.661
LDL 0.558 0.447–0.669
HgA1c 0.558 0.461–0.656
BNP 0.720 0.637–0.802 <
ardiac Mortality
TGL 0.676 0.558–0.795
HDL 0.542 0.413–0.67
LDL 0.564 0.433–0.695
HgA1c 0.518 0.400–0.635
BNP 0.779 0.700–0.858 <
Initial, i.e., at the time of enrollment into the study.
AUC  area under the curve; BNP  B-natriuretic peptide; CI  confidencriglycerides.resence of LV dysfunction but also predicts future risk may
e a valuable tool in reducing diabetic heart disease.
B-natriuretic peptide is a 32-aa polypeptide containing a
7-aa ring structure common to all natriuretic peptides (22).
t is found mainly in the cardiac ventricles, and its release
ppears to be directly proportional to ventricular volume
xpansion and pressure overload (4,23,24) B-natriuretic
eptide is an independent predictor of high LV end-
iastolic pressure (4) and correlates with both New York
eart Association functional classification and prognosis
25). A rapid assay for BNP has been cleared by the Food
nd Drug Administration as an aid in the diagnosis of
ongestive HF, and its use in this capacity has already been
elineated in recently published HF guidelines (26).
Despite the association between diabetes mellitus and
ncreased cardiovascular morbidity and mortality rates, the
revalence of myocardial systolic and diastolic functional
bnormalities in asymptomatic diabetic patients is not
ell-defined. A recent echocardiographic study of 66 nor-
otensive, asymptomatic subjects with type 2 diabetes
howed reduced LV systolic and diastolic function com-
ty, Specificity, Positive Predictive Value, Negative Predictive
rdiac Death) in Referred and Not-Referred Groups
Negative Predictive
Value Accuracy LR LR
86 (75–93) 54 1.45 0.40
85 (75–92) 58 1.58 0.42
82 (73–89) 59 1.57 0.53
82 (73–89) 61 2.20 0.26
97 (93–99) 61 1.70 0.52
96 (92–98) 74 2.10 0.63
96 (93–98) 80 2.63 0.64
96 (92–98) 82 2.71 0.69
95 (92–97) 85 3.07 0.72
95 (92–97) 87 5.66 0.55
es of Initial* TGL, HDL, LDL, HgA1c, and BNP in
Not-Referred
e AUC CI p Value
8 0.542 0.425–0.659 0.560
7 0.562 0.411–0.713 0.394
9 0.505 0.360–0.650 0.949
7 0.610 0.494–0.726 0.118
1 0.691 0.562–0.819 0.005
3 0.521 0.304–0.739 0.857
6 0.536 0.316–0.755 0.766
4 0.563 0.292–0.835 0.627
3 0.507 0.311–0.703 0.954
1 0.684 0.418–0.951 0.122
val; HDL  high-density lipoprotein; LDL  low-density lipoprotein; TGL sitivi
e Ca
ictive
)
)
)
)Valu
Valu
eath)
0.00
0.31
0.28
0.25
0.00
0.00
0.49
0.31
0.77
0.00
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September 1, 2004:1047–52 Prognostic Value of BNP in Diabeticsared with healthy subjects (27). Another study of 86
atients with type 2 diabetes free of cardiovascular disease
ound diastolic dysfunction in 41 of 86 patients (47%) (28).
iastolic dysfunction in type 2 diabetic patients is often
ound despite adequate metabolic control and freedom from
linically detectable disease (28). We found that 32 of 91
iabetic patients with no history of cardiac disease had
bnormal LV function on subsequent echocardiography
mean BNP level  161  40 pg/ml) (9). Of these 32
atients, 21 had diastolic dysfunction (BNP  190  60
g/ml). A ROC curve revealed the area under the curve was
.81 for patients without previous suspicion of cardiac
ysfunction (p  0.001).
The National Institutes of Health sponsored Studies Of
eft Ventricular Dysfunction (SOLVD) in patients with
symptomatic LV dysfunction demonstrated humoral acti-
ation characterized by increases in the natriuretic peptides
ithout activation of the circulating renin-angiotensin sys-
em (29). It has been shown that myocardial ischemia
ugments the synthesis and release of BNP even in the
bsence of myocardial necrosis or preexisting LV dysfunc-
ion. Recently, BNP levels have been shown to be prognos-
ically important in acute coronary syndromes (28,30).
eversible ischemia may transiently increase LV wall stress,
hich may be sufficient to cause an elevation in BNP levels.
hus, elevated BNP levels may not only indicate LV
ysfunction but also be a marker for myocardial ischemia
nd, therefore, prognosis.
Recently, the landmark paper by Wang et al. (31) found
hat, after adjusting for traditional risk factors, the level of
-type natriuretic peptide was independently predictive of the
isk of death, HF, atrial fibrillation, and stroke over a mean
ollow-up period of about five years. Levels of B-type natri-
retic peptide above the 80th percentile in this cohort (i.e.,
igure 3. Kaplan-Meier survival curves of the patients who died of all caus
nd 120 pg/ml in the patient groups without referral and with referral.igher than 20 pg/ml) were associated with an increase by vore than 60% in the long-term risk of death. Furthermore,
here was a significant prognostic gradient with respect to the
isk of HF, atrial fibrillation, and stroke among the three levels
f B-type natriuretic peptide (low, intermediate, and high)
xamined. This remarkable finding strongly suggests that there
re important prognostic data even in the range of B-type
atriuretic peptide levels thought, on the basis of previous
tudies, to rule out HF (i.e., levels below 100 pg/ml). Our
esults are consistent with these findings. We also saw a clear
ifference in survival in asymptomatic patients with  or 20
g/ml in our follow-up (p  0.004) with likelihood ratio of
1.7 (LR). But the decision statistics indicated a cut-point
f 120 pg/ml was better in decision-making in this subgroup of
atients (LR  5.66). This difference could be attributed to
eing the predominantly male diabetic population in our study
s compared with a community-based population in the
ramingham study. Our patients undoubtedly are a “sicker”
roup than the Framingham group, especially the group
eferred for possible cardiac disease. There is a high incidence
f ventricular dysfunction at the start of follow-up in this group
f patients. Even though the randomly selected 302 patients
ad no history of heart dysfunction, many not only had other
isk factors such as hypertension, but had underlying diastolic
ysfunction on echocardiography. Nonetheless, the magnitude
f risk that a high BNP implies is greater than implied by other
arkers such as high-density lipoprotein, low-density lipopro-
ein, and HgA1C.
tudy limitations. This was a prospective study done at a
ingle veterans hospital, so one must be careful about
eneralizing the results to the entire population. Both the
reas under the ROC curves and the negative predictive
alues are dependent on the patient population studied. Our
opulation represents generally older, predominantly male
cluding the cardiac death) with B-natriuretic peptide (BNP) values 120es (ineterans with a high prevalence of cardiac disease.
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Prognostic Value of BNP in Diabetics September 1, 2004:1047–52onclusions. In diabetic patients, whether referred for
chocardiography because of possible cardiac disease or
ompletely asymptomatic, BNP levels 120 pg/ml should
lert the caregiver to the likelihood of heart disease and a
igher risk of morbidity and mortality. We believe that
NP may be a cost-effective, easy-to-obtain, and useful
rognostic tool for risk stratification in diabetic patients and
an be used to assist in monitoring and preventing compli-
ations, which in turn may result in optimization of man-
gement and increased patient survival.
eprint requests and correspondence: Dr. Alan S. Maisel,
AMC Cardiology 111-A, 3350 La Jolla Village Drive, San
iego, California 92161. E-mail: amaisel@ucsd.edu.
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